Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients ...

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

New Delhi: Indian public health campaigners on Wednesday said they will oppose the patent applications of a promising new but ...

One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, ...

Lencapavir, which is dosed only every six months, is highly effective at preventing HIV, but advocates worry its cost will blunt its impact.

"It is crucial that Dr. Mezher retracts the incorrect claims from his TikTok." The post Viral Pic Of Bloody Toilet Paper ...

Standard treatment of babies with HIV typically starts two to three months after birth and continues for decades. This new ...

Drugmaker Gilead has announced that its new, twice-a-year shot ... approval from the U.S. Food and Drug Administration (FDA) to market lenacapavir as an HIV treatment. “With such remarkable ...

Drug companies typically only ensure drug access ... industry to grant permission for access while tens of thousands of new HIV infections accrue? In principle, solutions to enable access are ...

2024, 7, 8, 2379-2390) Efavirenz is an important drug for treating HIV infection ... a UMBC bioanalytical chemist and senior author on the new paper. “That formed the basis for investigating ...

The HIV drug which costs around $44,000 for twice-yearly ... Worldwide there are 1.3 million infections every year, with one new HIV infection every 24 seconds. Gilead has several patent ...